Benralizumab - AstraZeneca/Kyowa Kirin
Alternative Names: Benra; Benralizumab - AstraZeneca/Kyowa Hakko Kirin; Benralizumab - Kyowa-Hakko/AstraZeneca; BIW-8405; BIW-8405-IL-5R; Fasenra; KHK-4563; MEDI-563Latest Information Update: 25 Jul 2024
At a glance
- Originator BioWa
- Developer AstraZeneca; Kyowa Hakko; Kyowa Kirin; McMaster University; MedImmune; National Jewish Medical and Research Center
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antibronchitics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Asthma
- Preregistration Nasal polyps
- Phase III Chronic obstructive pulmonary disease; Churg-Strauss syndrome; Hypereosinophilic syndrome
- Phase II Atopic dermatitis; Rhinosinusitis
- No development reported Skin disorders
- Discontinued Bronchiectasis; Bullous pemphigoid; Chronic urticaria; Eosinophilic gastroenteritis; Eosinophilic oesophagitis
Most Recent Events
- 22 Jul 2024 AstraZeneca plans a phase III trial for Granulomatosis with polyangiitis (In Children, In adolescents) in September 2024 (NCT06512883)
- 12 Jun 2024 Updated efficacy data from a phase III MANDARA trial in Eosinophilic granulomatosis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR - 2024)
- 17 May 2024 Adverse events and pharmacodynamics data from the phase III trial in Churg-Strauss syndrome presented at the 120th International Conference of the American Thoracic Society (ATS-2024)